Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Following the current path, the colon cancer incidence rate will increase by 31.8% between 2003 and 2023 (447,000 people). If an alternative path is taken, there will be 17.7% (79,000…  
  • From 1975 to 1996, new cancer drugs increased life expectancy of cancer patients by about one year, at an estimated cost of $3,000—well below the estimated value of a statistical…  
  • Increase in 5-year survival rate for cancer
     
  • There are 3 million more cancer survivors today than there were a decade ago.  
  • According to NIH Director Elias Zerhouni, investments of $8.60 per person per year over 30 years has resulted in cancer deaths falling for the first time in “recorded history.”